...

FDA grants full approval to Pfizer's COVID vaccine in major pandemic milestone




  • In Business
  • 2021-08-23 14:37:00Z
  • By NY Daily News

The U.S. Food and Drug Administration granted full approval Monday to the COVID-19 vaccine developed by Pfizer and BioNTech, whose shots are now the first to move beyond emergency status since the pandemic began.

The highly anticipated move is effective for people 16 and older. The vaccine will remain available under emergency use authorization for children 12-15 years old and for a third dose in individuals with certain underlying medical conditions, according to the FDA.

"The FDA's approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic," Acting FDA Commissioner Janet Woodcock said in a statement.

"While this and other vaccines have met the FDA's rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product," she said.

The full approval was expected to boost confidence in the vaccine, potentially encouraging some of the 85 million unvaccinated Americans to get the shots. Months after the federal government made COVID-19 vaccines widely available and free to all adults, about 40% of people 12 and older still have not been vaccinated, according to the U.S. Centers for Disease Control and Prevention.

"While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," Woodcock said. "Today's milestone puts us one step closer to altering the course of this pandemic in the U.S."

Monday's announcement also means Pfizer and BioNTech will be allowed to market their vaccine, which is not permitted under emergency status. The two companies plan to market the vaccine as Comirnaty, the FDA said.

Pfizer Chairman and CEO Albert Bourla celebrated the accomplishment on social media.

"Every day, I wake up proud of our team at @Pfizer. Proud of the work we do. Proud of the difference we are making. And I am especially proud today," Bourla tweeted.

"It is our hope that this news will instill even further public confidence in our vaccine and the science that made it possible," he said.

---

COMMENTS

More Related News

CDC endorses COVID-19 vaccine boosters for people 65 and older, high-risk patients
CDC endorses COVID-19 vaccine boosters for people 65 and older, high-risk patients

The CDC endorsed booster shots for millions of older and high-risk Americans, opening a major new phase in the U.S vaccination drive against COVID-19.

CanSinoBIO
CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children -study
  • US
  • 2021-09-24 04:06:03Z

CanSino Biologics Inc's (CanSinoBIO) single-dose COVID-19 vaccine, given at a lower dosage than that for adults, is safe and triggers an immune response in...

Fact check: Why an FDA panel didn
Fact check: Why an FDA panel didn't recommend Pfizer's booster shot for all Americans

An advisory panel of the FDA did recommend a Pfizer booster shot for people 65 and older and those at high risk of severe illness.

McDonald
McDonald's restarts share buybacks as business recovers from pandemic hit

McDonald's had suspended its $15 billion buyback program early last year as the burger chain looked to conserve cash in order to navigate through the COVID...

Novavax applies to WHO for emergency listing of COVID-19 vaccine
Novavax applies to WHO for emergency listing of COVID-19 vaccine
  • US
  • 2021-09-23 13:35:44Z

The WHO's emergency use listing is a signal to national regulatory authorities on a product's safety and efficacy. It is also a prerequisite for export to...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business